ReviewBrain sciences2021
Imaging of Substantia Nigra in Parkinson's Disease: A Narrative Review.
Review in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A Mechanistic Understanding of the Different Factors Affecting Adaptation and Flexibility During Probabilistic Reversal Learning: A Neurocomputational Study on Patients with Parkinson's Disease and Control Subjects.Annals of biomedical engineering · 2026Article
- Biological heterogeneity in Parkinson's disease: implications for MRI-based patient stratification.NPJ Parkinson's disease · 2026Review
- Farnesol, a Dietary Sesquiterpene, Attenuates Rotenone-Induced Dopaminergic Neurodegeneration by Inhibiting Oxidative Stress, Inflammation, and Apoptosis via Mediation of Cell Signaling Pathways in Rats.International journal of molecular sciences · 2026Article
- Nuclear Medicine Imaging Biomarkers in Parkinson's Disease: Past, Present, and Future Directions.Medical sciences (Basel, Switzerland) · 2025Review
- The Dopaminergic and Anti-Neuroinflammatory Properties of Functionalized Nanoliposomes Containing Levodopa and Ibuprofen and Conjugated with Anti-Alpha-Synuclein Aptamer.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Fast whole brain relaxometry with Magnetic Resonance Spin TomogrAphy in Time-domain (MR-STAT) at 3 T: a retrospective cohort study.Magma (New York, N.Y.) · 2025Article
- Economic value of AI-based MRI triage for Parkinson's disease: a cost-benefit study in South Korea and the United States.Frontiers in public health · 2025Article
- Substantia nigra and locus coeruleus microstructural abnormalities in isolated rapid eye movement sleep behaviour disorder and Parkinson's disease.Brain communications · 2025Article
- Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations.Brain : a journal of neurology · 2024Article
- Review
- Aggregated Pattern Classification Method for improving neural disorder stage detection.Brain and behavior · 2024Article
- Parkinson's image detection and classification based on deep learning.BMC medical imaging · 2024Article
- Microglia in Neurodegenerative Diseases.Advances in neurobiology · 2024Review
- PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2024Review
- Disease-Modifying Effects of Vincamine Supplementation inACS chemical neuroscience · 2023Article
- Distinguishing Parkinson's Disease with GLCM Features from the Hankelization of EEG Signals.Diagnostics (Basel, Switzerland) · 2023Article
- Radiomic and clinical nomogram for cognitive impairment prediction in Wilson's disease.Frontiers in neurology · 2023Article
- Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson's Disease.International journal of molecular sciences · 2022Review
- A brief history of brain iron accumulation in Parkinson disease and related disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Magnetic resonance imaging of the dopamine system in schizophrenia - A scoping review.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder, characterized by motor and non-motor symptoms due to the degeneration of the pars compacta of the substantia nigra (SNc) with dopaminergic denervation of the striatum. Although the diagnosis of PD is principally based on a clinical assessment, great efforts have been expended over the past two decades to evaluate reliable biomarkers for PD. Among these biomarkers, magnetic resonance imaging (MRI)-based biomarkers may play a key role. Conventional MRI sequences are considered by many in the field to have low sensitivity, while advanced pulse sequences and ultra-high-field MRI techniques have brought many advantages, particularly regarding the study of brainstem and subcortical structures. Nowadays, nigrosome imaging, neuromelanine-sensitive sequences, iron-sensitive sequences, and advanced diffusion weighted imaging techniques afford new insights to the non-invasive study of the SNc. The use of these imaging methods, alone or in combination, may also help to discriminate PD patients from control patients, in addition to discriminating atypical parkinsonian syndromes (PS). A total of 92 articles were identified from an extensive review of the literature on PubMed in order to ascertain the-state-of-the-art of MRI techniques, as applied to the study of SNc in PD patients, as well as their potential future applications as imaging biomarkers of disease. Whilst none of these MRI-imaging biomarkers could be successfully validated for routine clinical practice, in achieving high levels of accuracy and reproducibility in the diagnosis of PD, a multimodal MRI-PD protocol may assist neuroradiologists and clinicians in the early and differential diagnosis of a wide spectrum of neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.